Zentalis Pharmaceuticals Inc
Closed
4.05 -0.98
Overview
Share price change
24h
Min
4.01
Max
4.09
Income | -8.5M -35M |
|---|---|
Employees | 106 |
EBITDA | -11M -37M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +72.84% upside |
Next Earnings | 19 May 2026 |
|---|
Market Cap | 131M 295M |
|---|---|
Previous open | 5.03 |
Previous close | 4.05 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Zentalis Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zentalis Pharmaceuticals Inc Forecast
Price Target
By TipRanks
72.84% upside
12 Months Forecast
Average 7 USD 72.84%
High 10 USD
Low 4 USD
Based on 7 Wall Street analysts offering 12 month price targets forZentalis Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
